Sanofi Japan and Taiwan-based startup Health2Sync have entered into a partnering agreement to support healthcare professionals and people living with diabetes mellitus through digital support programs.

Health2Sync, a digital health startup, specializing in diabetes and other chronic disease management, has developed a healthcare/lifestyle app that has been used by about 290,000 users in Japan.

Through this partnering agreement, Sanofi and Health2Sync will work together to develop digitized features for healthcare providers and patients on insulin in Japan that will help improve Hypoglycemia/Hyperglycemia insulin management by connected caps for insulin, and titration alerts, to people living with diabetes.

The two companies initiated their collaboration in Taiwan in September 2020 by providing digital health solutions to healthcare professionals and patients and have witnessed a good adoption within more than 200 clinics and more than 10,000 insulin patients having already joined the program as of May 2022.

This agreement in Japan again emphasizes the companies' ambition to realize a more comprehensive chronic disease management through digital solutions. 

Moving forward, Sanofi and Health2Sync plan to further collaborate in bringing innovative digital therapeutics solutions to patients and healthcare professionals in Japan and other markets.